SLS Short Interest Hits All-Time High at 33% as Executive Severance Changes Fuel Buyout Speculation

According to Koyfin data, short interest in Sellas Life Sciences Group (SLS) climbed to nearly 33% of the float as of June 15, marking an all-time high, up sharply from 25.5% at the start of April. The surge follows the company's announcement on Thursday of amended severance agreements for CEO Angelos Stergiou, CFO John Burns, and Chief Development Officer Dragan Cicic, which sparked renewed buyout speculation on social platforms.

SLS shares surged nearly 15% in the previous session and are on track for their strongest weekly performance in six weeks. The stock's Phase 3 Regal trial evaluating Galinpepimut-S in acute myeloid leukemia patients remains a key catalyst, with the study approaching the 80-event threshold for final overall survival analysis.